Actively Recruiting
Randomized, Double-Blind Study of Olpasiran to Prevent First Major Cardiovascular Events in People With High Lipoproteina
Led by Amgen · Updated on 2026-08-21
11000
Participants Needed
252
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effect of olpasiran compared to a placebo on the risk of coronary heart disease death, heart attack, or urgent coronary revascularization in people at risk for a first major cardiovascular event who have elevated lipoproteina levels. This phase 3 study focuses on participants aged 50 to 105 years with multiple cardiovascular risk factors or evidence of atherosclerosis. Participants will be randomly assigned to receive either subcutaneous injections of olpasiran or a placebo. The study is designed as a double-blind, placebo-controlled trial, meaning neither participants nor researchers know who receives the active drug or placebo. The treatment period spans up to approximately 6.2 years, during which participants receive regular injections and monitoring. Throughout the study, participants will be assessed for the time until coronary heart disease death, myocardial infarction, or urgent coronary revascularization occurs. Additional measurements include changes in lipoproteina levels and monitoring of cardiovascular events, strokes, and safety through adverse event tracking. Participants will have regular evaluations over the treatment duration, ensuring close follow-up until study completion.
CONDITIONS
Brief Title
OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events
Research Team
A
Amgen Call Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here